- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Alex Bastian Strives to Define Value in Care Better
In order to reign in high costs of care in oncology, the healthcare community needs to be able to define value better, according to Alex Bastian, MBA, senior vice president at GfK.
In order to reign in high costs of care in oncology, the healthcare community needs to be able to define value better, according to Alex Bastian, MBA, senior vice president at GfK.
He is looking at initiatives like Choosing Wisely and the American Society of Clinical Oncology’s value task force to help providers more rationally use resources. And, he added, it is critical to include patients.
“I think the patient’s voice also needs to come out more clearly,” Mr Bastian said. “As the patient gets more involved, they need to articulate what value looks like.”
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities
April 22nd 2025Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom documentation and burden vary across certain demographics.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
